Improved pharmacokinetic characteristics and bioactive effects of anticancer enzyme delivery systems

References

• Global Burden of Disease Cancer Collaboration. Fitzmaurice C, Akinyemiju TF, Al Lami FH, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018; [PMID: 29860482]. DOI:10.1001/jamaoncol.2018.2706
   Web of Science ®Google Scholar
• Znaor A, van den Hurk C, Primic-Zakeljx M, et al. Cancer incidence and mortality patterns in South Eastern Europe in the last decade: gaps persist compared with the rest of Europe. Eur J Cancer. 2013;49:1683–1691. PubMed: 23265703.
   PubMed Web of Science ®Google Scholar
• Pokrovsky VS, Chepikova OE, Davydov DZ, et al. Amino acid degrading enzymes and their application in cancer therapy. Curr Med Chem. 2017; DOI:10.2174/0929867324666171006132729. [PMID: 28990519].
   PubMedGoogle Scholar
• Chhim RF, Shelton CM, Christensen ML. Recent new drug approvals, part 2: drugs undergoing active clinical studies in children. J Pediatr Pharmacol Ther. 2013;18(1):14–38. [PMID: 23616733].
   PubMedGoogle Scholar
• Verma MK, Pulicherla KK. Enzyme promiscuity in earthworm serine protease: substrate versatility and therapeutic potential. Amino Acids. 2016;48:941–948. [PubMed: 26739820]
   PubMed Web of Science ®Google Scholar
• Yang L, Yan S, Zhang Y, et al. Novel enzyme formulations for improved pharmacokinetic properties and anti-inflammatory efficacies. Int J Pharm. 2018;537(1–2):268–277.
   PubMedGoogle Scholar
• Asselin B, Rizzari C. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma. 2015;56:2273–2280. PubMed: 25586605
   PubMed Web of Science ®Google Scholar
• Hunault-Berger M, Leguay T, Huguet F, et al. A phase 2 study of l-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: the GRASPALL/GRAALL-SA2-2008 study. Am J Hematol. 2015;90:811–818. PubMed: 26094614.
   PubMed Web of Science ®Google Scholar
• Yau T, Cheng PN, Chan P, et al. A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. Invest. New Drugs. 2013;31:99–107. PubMed: 22426640.
   PubMed Web of Science ®Google Scholar
• Zhu L, Wu Z, Jin JM, et al. Directed evolution of leucine dehydrogenase for improved efficiency of l-tert-leucine synthesis. Appl Microbiol Biotechnol. 2016;100(13):513–5805. PMID: 26898942.
   Web of Science ®Google Scholar
• Turgut Kara N, Çakır Ö, Arıkan B, et al. Molecular cloning and biotic elicitation response of phenylalanine ammonia-lyase gene of Astragalus chrysochlorus. Cell Mol Biol (Noisy-Le-Grand). 2018;64(5):102–106. [PMID: 29729701].
   PubMed Web of Science ®Google Scholar
• Swami R, Shahiwala A. Impact of physiochemical properties on pharmacokinetics of protein therapeutics. Eur J Drug Metab Pharmacokinet. 2013;38(4):231–239.
   PubMed Web of Science ®Google Scholar
• Reda FM. Kinetic properties of Streptomyces canarius l-glutaminase and its anticancer efficiency. Braz J Microbiol. 2015;46:957–968. PubMed: 26691453
   PubMed Web of Science ®Google Scholar
• Han RZ, Xu GC, Dong JJ, et al. Arginine deiminase: recent advances in discovery, crystal structure, and protein engineering for improved properties as an anti-tumor drug. Appl Microbiol Biotechnol. 2016;100:4747–4760. PubMed: 27087524.
   PubMed Web of Science ®Google Scholar
• Ni Y, Schwaneberg U, Sun ZH. Arginine deiminase, a potential anti-tumor drug. Cancer Lett. 2008;261:1–11. PubMed: 18179862
   PubMed Web of Science ®Google Scholar
• Sharma B, Singh S, Kanwar SS. l-Methionase: a therapeutic enzyme to treat malignancies. Biomed Res Int. 2014;2014:506287. PubMed: 25250324.
   Google Scholar
• Batool T, Makky EA, Jalal M, et al. A comprehensive review on l-asparaginase and its applications. Appl Biochem Biotechnol. 2016;178:900–923. PubMed: 26547852.
   PubMed Web of Science ®Google Scholar
• Shrivastava A, Khan AA, Khurshid M, et al. Recent developments in l-asparaginase discovery and its potential as anticancer agent. Crit Rev Oncol Hematol. 2016;100:1–10. PubMed: 25630663.
   PubMed Web of Science ®Google Scholar
• Cheng PN, Lam TL, Lam WM, et al. Pegylated recombinant human arginase (rhArg-peg5.000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res. 2007;67:309–317. PubMed: 17210712.
   PubMed Web of Science ®Google Scholar
• Covini D, Tardito S, Bussolati O, et al. Expanding targets for a metabolic therapy of cancer: l-asparaginase. Recent Pat Anticancer Drug Discov. 2012;7:4–13. PubMed: 21854356.
   PubMed Web of Science ®Google Scholar
• Pokrovsky VS, Chepikova OE, Davydov DZ, et al. Amino acid degrading enzymes and their application in cancer therapy. Curr Med Chem. 2017; DOI:10.2174/0929867324666171006132729. [PMID: 28990519].
   PubMedGoogle Scholar
• Plourde PV, Jeha S, Hijiya N, et al. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial. Pediatr Blood Cancer. 2014;61:1232–1238. PubMed: 24436152.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Kirov II, Dreyer ZE, et al. Activity and toxicity of intravenous Erwinia asparaginase following allergy to E. coli-derived asparaginase in children and adolescents with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016;63:228–233. PubMed: 26376459.
   PubMed Web of Science ®Google Scholar
• Tomlinson BK, Thomson JA, Bomalaski JS, et al. Phase I trial of arginine deprivation therapy with ADI-PEG 20 plus docetaxel in patients with advanced malignant solid tumors. Clin Cancer Res. 2015;21:2480–2486. PubMed: 25739672.
   PubMed Web of Science ®Google Scholar
• Bachet JB, Gay F, Maréchal R, et al. Asparagine synthetase expression and phase I study with l-asparaginase encapsulated in red blood cells in patients with pancreatic adenocarcinoma. Pancreas. 2015;44:1141–1147. PubMed: 26355551.
   PubMed Web of Science ®Google Scholar
• Fultang L, Vardon A, De-Santo C, et al. Molecular basis and current strategies of therapeutic arginine depletion for cancer. Int J Cancer. 2016;139:501–509. PubMed: 26913960.
   PubMed Web of Science ®Google Scholar
• Tanios R, Bekdash A, Kassab E, et al. Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells. Leuk Res. 2013;37:1565–1571. PubMed: 24018014.
   PubMed Web of Science ®Google Scholar
• Marini JC, Didelija IC. Arginine depletion by arginine deiminase does not affect whole protein metabolism or muscle fractional protein synthesis rate in mice. PLoS ONE. 2015;10:e0119801. PubMed: 25775142
   PubMed Web of Science ®Google Scholar
• Nguyen HA, Su Y, Zhang JY, et al. A novel l-asparaginase with low l-glutaminase coactivity is highly efficacious against both T- and B-cell acute lymphoblastic leukemias in vivo. Cancer Res. 2018;78(6):1549–1560. [PMID: 29343523].
   PubMed Web of Science ®Google Scholar
• Ortac I, Simberg D, Yeh YS, et al. Dual-porosity hollow nanoparticles for the immunoprotection and delivery of nonhuman enzymes. Nano Lett. 2014;14:3023–3032. PubMed: 24471767.
   PubMed Web of Science ®Google Scholar
• Burrows N, Cane G, Robson M, et al. Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20). Sci Rep. 2016;6:22950. PubMed: 26972697.
   PubMed Web of Science ®Google Scholar
• Agostinelli E, Vianello F, Magliulo G, et al. Nanoparticle strategies for cancer therapeutics: nucleic acids. Polyamines, bovine serum amine oxidase and iron oxide nanoparticles (Review). Int J Oncol. 2015;46:5–16. PubMed: 25333509.
   PubMed Web of Science ®Google Scholar
• Vasudev SS, Ahmad S, Parveen R, et al. Formulation of PEG-ylated l-asparaginase loaded poly (lactide-co-glycolide) nanoparticles: influence of pegylation on enzyme loading, activity and in vitro release. Pharmazie. 2011;66:956–960. PubMed: 22312702.
   PubMed Web of Science ®Google Scholar
• Xin L, Zhang HT, Yang WF, et al. Evaluation of METase-pemetrexed-loaded PEG-PLGA nanoparticles modified with anti-CD133-scFV for treatment of gastric carcinoma. Biosci Rep. 2018;38(1). DOI:10.1042/BSR20171001 PMID: 29229675.
   PubMedGoogle Scholar
• Gil MS, Cho J, Thambi T, et al. Bioengineered robust hybrid hydrogels enrich the stability and efficacy of biological drugs. J Control Release. 2017;267:119–132. PubMed: 28412223.
   PubMed Web of Science ®Google Scholar
• Ott PA, Carvajal RD, Pandit-Taskar N, et al. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest. New Drugs. 2013;31:425–434. PubMed: 22864522.
   PubMed Web of Science ®Google Scholar
• El-Sayed AS, Shouman SA, Nassrat HM. Pharmacokinetics, immunogenicity and anticancer efficiency of Aspergillus flavipes l-methioninase. Enzyme Microb Technol. 2012;51:200–210. PubMed: 22883554
   PubMed Web of Science ®Google Scholar
• Bahreini E, Aghaiypour K, Abbasalipourkabir R, et al. Preparation and nanoencapsulation of l-asparaginase II in chitosan-tripolyphosphate nanoparticles and in vitro release study. Nanoscale Res Lett. 2014;9:340. PubMed: 25114635.
   PubMed Web of Science ®Google Scholar
• Baskar G, Chandhuru J, Sheraz Fahad K, et al. Anticancer activity of fungal l-asparaginase conjugated with zinc oxide nanoparticles. J Mater Sci Mater Med. 2015;26:5380. PubMed: 25589205.
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Anvari N. Enhanced stability of l-asparaginase by its bioconjugation to poly(styrene-co-maleic acid) and Ecoflex nanoparticles. IET Nanobiotechnol. 2018;12(4):466–472. [PMID:29768231].
   PubMed Web of Science ®Google Scholar
• Wang F, Zhang YQ. Bioconjugation of silk fibroin nanoparticles with enzyme and peptide and their characterization. Adv Protein Chem Struct Biol. 2015;98:263–291. PubMed: 25819282
   PubMed Web of Science ®Google Scholar
• Venditti I, Hassanein TF, Fratoddi I, et al. Bioconjugation of gold-polymer core-shell nanoparticles with bovine serum amine oxidase for biomedical applications. Colloids Surf B Biointerfaces. 2015;134:314–321. PubMed: 26209964.
   PubMed Web of Science ®Google Scholar
• Ulu A, Ozcan I, Koytepe S, et al. Design of epoxy-functionalized Fe3O4@MCM-41 core-shell nanoparticles for enzyme immobilization. Int J Biol Macromol. 2018;115:1122–1130. [PMID: 29727644].
   PubMed Web of Science ®Google Scholar
• Sinigaglia G, Magro M, Miotto G, et al. Catalytically active bovine serum amine oxidase bound to fluorescent and magnetically drivable nanoparticles. Int J Nanomedicine. 2012;7:2249–2259. PubMed: 22619559.
   PubMed Web of Science ®Google Scholar
• Pandian SR, Deepak V, Nellaiah H, et al. PEG-PHB-glutaminase nanoparticle inhibits cancer cell proliferation in vitro through glutamine deprivation. Dev Biol Anim. 2015;51:372–380. PubMed: 25424834.
   PubMed Web of Science ®Google Scholar
• Muthukumar T, Chamundeeswari M, Prabhavathi S, et al. Carbon nanoparticle from a natural source fabricated for folate receptor targeting, imaging and drug delivery application in A549 lung cancer cells. Eur J Pharm Biopharm. 2014;88:730–736. PubMed: 25305584.
   PubMed Web of Science ®Google Scholar
• Kurinomaru T, Shiraki K. Noncovalent PEGylation of l-asparaginase using PEGylated polyelectrolyte. J. Pharm. Sci. 2015;104(2):587–592. PubMed: 25354692.
   PubMed Web of Science ®Google Scholar
• Kwon YM, Chung HS, Moon C, et al. l-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL). J Control Release. 2009;139:182–189. PubMed: 19577600.
   PubMed Web of Science ®Google Scholar
• Xin L, Caot JQ, Liu C, et al. Evaluation of rMETase-loaded stealth PLGA/liposomes modified with anti-CAGE scFV for treatment of gastric carcinoma. J Biomed Nanotechnol. 2015;11:1153–1161. PubMed: 19577600.
   PubMed Web of Science ®Google Scholar
• Wu FL, Yeh TH, Chen YL, et al. Intracellular delivery of recombinant arginine deiminase (rADI) by heparin-binding hemagglutinin adhesion peptide restores sensitivity in rADI-resistant cancer cells. Mol Pharm. 2014;11:2777–2786. PubMed: 24950134.
   PubMed Web of Science ®Google Scholar
• Zeng T, Zhang Y, Yan Q, et al. Construction and in vitro evaluation of enzyme nanoreactors based on carboxymethyl chitosan for arginine deprivation in cancer therapy. Carbohydr Polym. 2017;162:35–41. PMID: 28224892.
   PubMed Web of Science ®Google Scholar
• Tabandeh MR, Aminlari M. Synthesis, physicochemical and immunological properties of oxidized inulin-l-asparaginase bioconjugate. J Biotechnol. 2009;141:189–195. PubMed: 19433225
   PubMed Web of Science ®Google Scholar
• Yang W, Zhang H, Xin L. A novel design of HA-coated nanoparticles co-encapsulating plasmid METase and 5-Fu shows enhanced application in targeting gastric cancer stem cells. Biol Chem. 2018;399(3):293–303. PMID: 29016350.
   PubMed Web of Science ®Google Scholar
• Angiolillo AL, Schore RJ, Devidas M, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli l-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from children’s oncology group study AALL07P4. J Clin Oncol. 2014;32:3874–3882. PubMed: 25348002.
   PubMed Web of Science ®Google Scholar
• Ashrafi H, Amini M, Mohammadi-Samani S, et al. Nanostructure l-asparaginase-fatty acid bioconjugate: synthesis, preformulation study and biological assessment. Int J Biol Macromol. 2013;62:180–187. PubMed: 23994737.
   PubMed Web of Science ®Google Scholar
• Yeh TH, Chen YR, Chen SY, et al. Selective intracellular delivery of recombinant arginine deiminase (ADI) using pH-sensitive cell penetrating peptides to overcome ADI resistance in hypoxic breast cancer cells. Mol Pharm. 2016;13:262–271. PubMed: 26642391.
   PubMedGoogle Scholar
• Borghorst S, Hempel G, Poppenborg S, et al. Comparative pharmacokinetic/pharmacodynamic characterisation of a new pegylated recombinant E. coli l-asparaginase preparation (MC0609) in beagle dog. Cancer Chemother Pharmacol. 2014;74:367–378. PubMed: 24934864.
   PubMed Web of Science ®Google Scholar
• Poppenborg SM, Wittmann J, Walther W, et al. Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice. Eur J Pharm Sci. 2016;91:122–130. PubMed: 27292820.
   PubMed Web of Science ®Google Scholar
• Wan S, He D, Yuan Y, et al. Chitosan-modified lipid nanovesicles for efficient systemic delivery of l-asparaginase. Colloids Surf B: Biointerfaces. 2016;143:278–284. PubMed: 27022867.
   PubMed Web of Science ®Google Scholar
• Takaku H, Takase M, Abe S, et al. In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini. Int J Cancer. 1992;51:244–249. PubMed: 1568792.
   PubMed Web of Science ®Google Scholar
• Zhang L, Liu M, Jamil S, et al. PEGylation and pharmacological characterization of a potential anti-tumor drug, an engineered arginine deiminase originated from Pseudomonas plecoglossicida. Cancer Lett. 2015;357:346–354. PubMed: 25462857.
   PubMed Web of Science ®Google Scholar
• Yau T, Cheng PN, Chan P, et al. Preliminary efficacy, safety, pharmacokinetics. pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2015;33:496–504. PubMed: 25666409.
   PubMed Web of Science ®Google Scholar
• Yang Z, Wang J, Lu Q, et al. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res. 2004;64:6673–6678. PubMed: 15374983.
   PubMed Web of Science ®Google Scholar
• Ivens IA, Achanzar W, Baumann A, et al. PEGylated biopharmaceuticals: current experience and considerations for nonclinical development. Toxicol Pathol. 2015;43:959–983. PubMed: 26239651.
   PubMed Web of Science ®Google Scholar
• Pippa N, Merkouraki M, Pispas S, et al. DPPC:MPOx chimeric advanced drug delivery nano systems chi-aDDnSs: physicochemical and structural characterization, stability and drug release studies. Int J Pharm. 2013;450:1–10. PubMed: 23618959.
   PubMed Web of Science ®Google Scholar
• Liu X, Situ A, Kang Y, et al. Irinotecan delivery by lipid-coated mesoporous silica nanoparticles shows improved efficacy and safety over liposomes for pancreatic cancer. ACS Nano. 2016;10:2702–2715. PubMed.
   PubMed Web of Science ®Google Scholar
• Yu M, Guo F, Tan F, et al. Dual-targeting nanocarrier system based on thermosensitive liposomes and gold nanorods for cancer thermo-chemotherapy. J Control Release. 2015;215:91–100. PubMed: 26256259.
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Lukyanov AN. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today. 2003;8(6):259–266. PubMed: 12623240.
   PubMed Web of Science ®Google Scholar